Cytomegalovirus infection: Its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: A single-center experience

Liver Transplantation

Volumn 18, Issue 12, 2012, Pages 1448-1455

  Wadhawan, Manav ^a   Gupta, Subash ^a   Goyal, Neerav ^a   Vasudevan, Karisangal R ^a   Makki, Kausar ^a   Dawar, Reetika ^a   Sardana, Raman ^a   Lal, Nand ^a   Kumar, Ajay ^a  

^a INDRAPRASTHA APOLLO HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOGLOBULIN G ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISOLONE; TACROLIMUS; VALGANCICLOVIR; VIRUS DNA;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG INDICATION; DRUG MEGADOSE; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFANT; LIVER GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS DETECTION; VIRUS REACTIVATION;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INDIA; INFANT; KAPLAN-MEIER ESTIMATE; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS ACTIVATION; YOUNG ADULT;

EID: 84870895728     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23540     Document Type: Article

References (15)

1. Balfour HH Jr, Chace BA, Stapleton JT, Simmons RL, Fryd DS,. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989; 320: 1381 -1387.
2. Gane E, Saliba F, Valdecasas GJ, O'Grady J, Pescovitz MD, Lyman S, Robinson CA,. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 1997; 350: 1729 -1733.
3. Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340: 1462 -1470.
4. Barkholt L, Lewensohn-Fuchs I, Ericzon BG, Tydén G, Andersson J,. High-dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients. Transpl Infect Dis 1999; 1: 89 -97.
5. Razonable RR,. Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J Gastroenterol 2008; 14: 4849 -4860.
6. Singh N, Wannstedt C, Keyes L, Wagener MM, Cacciarelli TV,. Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection? Liver Transpl 2005; 11: 700 -704.
7. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG,. Meta-Analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870 -880.
8. Kim JM, Kim SJ, Joh JW, Kwon CH, Song S, Shin M, et al. Is cytomegalovirus infection dangerous in cytomegalovirus-seropositive recipients after liver transplantation? Liver Transpl 2011; 17: 446 -455.
9. Kothari A, Ramachandran VG, Gupta P, Singh B, Talwar V,. Seroprevalence of cytomegalovirus among voluntary blood donors in Delhi, India. J Health Popul Nutr 2002; 20: 348 -351.
10. Ljungman P, Griffiths P, Paya C,. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094 -1097.
11. Huprikar S,. Update in infectious diseases in liver transplant recipients. Clin Liver Dis 2007; 11: 337 -354.
12. Limaye AP, Bakthavatsalam R, Kim HW, Randolph SE, Halldorson JB, Healey PJ, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81: 1645 -1652.
13. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, et al.; for Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611 -620.
14. Limaye AP, Bakthavatsalam R, Kim HW, Kuhr CS, Halldorson JB, Healey PJ, Boeckh M,. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004; 78: 1390 -1396.
15. Razonable RR, Rivero A, Rodriguez A, Wilson J, Daniels J, Jenkins G, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001; 184: 1461 -1464.